Fredun Pharmaceuticals Ltd - 539730 - Corporate Action-Board approves Dividend
Final Dividend @ 7%07-05-2024
07-05-2024
Fredun Pharmaceuticals Ltd - 539730 - Standalone Audited Financial Results For The Quarter And Financial Year Ended March 31, 2024
Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 202407-05-2024
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting 07.05.2024
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 07, 2024 has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2024 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2023-24; subject to the approval of the Shareholders at the ensuing 37th Annual General Meeting of the Company;07-05-2024
Fredun Pharmaceuticals Ltd - 539730 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyFredun Pharmaceuticals Ltd 2CIN NO.L24239MH1987PLC043662 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 48.93 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Jinkal Soni Designation: Company Secretary and Compliance Officer EmailId: cs@fredungroup.com Name of the Chief Financial Officer: Fredun Medhora Designation: Chief Financial Officer EmailId: fredun@fredungroup.com Date: 30/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2024
Fredun Pharmaceuticals Ltd - 539730 - Yearly Certificate Under Reg 40(9) Of LODR Reg, 2015
Yearly Certificate under Reg 40 (9) of LODR Reg, 201529-04-2024
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Tuesday, 07Th May, 2024.
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 ,inter alia, to consider and approve Notice is hereby given pursuant to Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the meeting of the Board of Directors of Fredun Pharmaceuticals Limited is scheduled to be held on Tuesday, 07th May, 2024 inter alia, to consider and approve the following: 1. Consider and approve Audited Financial Results for the Financial Year ended March 31, 2024 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date. 2. Consider and recommend final dividend on the paid-up equity shares for the Financial Year ended March 31, 2024.24-04-2024
Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under reg 74(5) of SEBI (DP) Reg, 201815-04-2024
Fredun Pharmaceuticals Ltd - 539730 - Compliance Certificate For The Period Ended March 31, 2024
Compliance certificate for the period ended March 31, 202415-04-2024
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Allotment Of 20,000 Equity Shares To Non-Promoter Upon Conversion Of Warrants Into Equity Shares
Allotment of 20,000 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares15-04-2024
Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window
Closure of Trading Window30-03-2024